Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 92.87 billion. The enterprise value is 76.54 billion.

Market Cap	92.87B
Enterprise Value	76.54B

Important Dates

The next estimated earnings date is Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 63.52 million shares outstanding. The number of shares has decreased by -1.23% in one year.

Current Share Class	n/a
Shares Outstanding	63.52M
Shares Change (YoY)	-1.23%
Shares Change (QoQ)	-1.51%
Owned by Insiders (%)	1.07%
Owned by Institutions (%)	51.50%
Float	62.85M

Valuation Ratios

The trailing PE ratio is 20.25 and the forward PE ratio is 18.55. Genmab's PEG ratio is 0.98.

PE Ratio	20.25
Forward PE	18.55
PS Ratio	4.76
PB Ratio	2.91
P/TBV Ratio	5.16
P/FCF Ratio	14.13
P/OCF Ratio	n/a
PEG Ratio	0.98

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.01, with an EV/FCF ratio of 11.65.

EV / Earnings	16.28
EV / Sales	3.86
EV / EBITDA	11.01
EV / EBIT	11.66
EV / FCF	11.65

Financial Position

The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.03.

Current Ratio	5.17
Quick Ratio	5.15
Debt / Equity	0.03
Debt / EBITDA	0.14
Debt / FCF	0.15
Interest Coverage	149.16

Financial Efficiency

Return on equity (ROE) is 14.92% and return on invested capital (ROIC) is 12.66%.

Return on Equity (ROE)	14.92%
Return on Assets (ROA)	10.95%
Return on Capital (ROIC)	12.66%
Revenue Per Employee	7.53M
Profits Per Employee	1.78M
Employee Count	2,204
Asset Turnover	0.53
Inventory Turnover	10.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.39% in the last 52 weeks. The beta is 0.86, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-31.39%
50-Day Moving Average	1,526.76
200-Day Moving Average	1,793.72
Relative Strength Index (RSI)	42.97
Average Volume (20 Days)	110,428

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 19.84 billion and earned 4.70 billion in profits. Earnings per share was 72.21.

Revenue	19.84B
Gross Profit	19.07B
Operating Income	6.56B
Pretax Income	6.57B
Net Income	4.70B
EBITDA	6.86B
EBIT	6.56B
Earnings Per Share (EPS)	72.21

Full Income Statement

Balance Sheet

The company has 17.32 billion in cash and 987.00 million in debt, giving a net cash position of 16.33 billion or 257.08 per share.

Cash & Cash Equivalents	17.32B
Total Debt	987.00M
Net Cash	16.33B
Net Cash Per Share	257.08
Equity (Book Value)	31.92B
Book Value Per Share	502.60
Working Capital	19.11B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.73 billion and capital expenditures -160.00 million, giving a free cash flow of 6.57 billion.

Operating Cash Flow	6.73B
Capital Expenditures	-160.00M
Free Cash Flow	6.57B
FCF Per Share	103.44

Full Cash Flow Statement

Margins

Gross margin is 96.10%, with operating and profit margins of 33.07% and 23.69%.

Gross Margin	96.10%
Operating Margin	33.07%
Pretax Margin	33.10%
Profit Margin	23.69%
EBITDA Margin	34.54%
EBIT Margin	33.07%
FCF Margin	33.11%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.23%
Shareholder Yield	1.23%
Earnings Yield	4.94%
FCF Yield	7.08%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 12.28.

Altman Z-Score	12.28
Piotroski F-Score	n/a